PIK3CA and colorectal carcinoma: Here, we aimed to utilize the HCT-116 human colon carcinoma cell line (mut PIK3CA, mut KRASG13D, and MMR deficient) and HT-29 human colorectal adenocarcinoma cell line (mut PIK3CA, mut BRAFV600E, and mut TP53) as CRC preclinical models to investigate the therapeutic potential of PRO in combination with CAP.